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serum Concentrations of 
Citrate, Tyrosine, 2- and 3- 
Hydroxybutyrate are Associated 
with Increased 3-Month Mortality 
in Acute Heart Failure Patients
sarah stryeck1, Michaela Gastrager1, Vesna Degoricija2,3, Matias trbušić2,3, Ines Potočnjak3, 
Bojana Radulović4, Gudrun pregartner5, Andrea Berghold5, Tobias Madl  1,6 & Saša Frank1,6
Considering the already established relationship between the extent of the metabolic dysfunction and 
the severity of heart failure (HF), it is conceivable that the metabolomic profile of the serum may have 
a prognostic capacity for 3-month mortality in acute heart failure (AHF). Out of 152 recruited patients, 
130 serum samples were subjected to the metabolomic analyses. The 3-month mortality rate was 
24.6% (32 patients). Metabolomic profiling by nuclear magnetic resonance spectroscopy found that 
the serum levels of 2-hydroxybutyrate (2-HB), 3-hydoxybutyrate (3-HB), lactate, citrate, and tyrosine, 
were higher in patients who died within 3 months compared to those who were alive 3 months after 
onset of AHF, which was confirmed by univariable logistic regression analyses (p = 0.009, p = 0.005, 
p = 0.008, p<0.001, and p<0.001, respectively). These associations still remained significant for all 
tested metabolites except for lactate after adjusting for established prognostic parameters in HF. In 
conclusion, serum levels of 2-HB, 3-HB, tyrosine, and citrate measured at admission are associated with 
an increased 3-month mortality rate in AHF patients and might thus be of prognostic value in AHF.
Heart failure (HF) is a final stage of various cardiovascular diseases and a common cause of disability and death1. 
The European Society of Cardiology (ESC) defines HF as an abnormality of the cardiac structure and function, 
which results in a diminished oxygen supply to the metabolizing tissues2,3. Acute heart failure (AHF) is primarily 
characterized by the rapid onset of symptoms and signs of HF3.
Metabolic dysfunction, an inherent feature of the HF pathophysiology4,5, reflects not only the altered metab-
olism of the myocardium but rather overall contributions from peripheral tissues and organs6. Hemodynamic 
impairment and the thereby accompanied tissue hypoperfusion and congestion increase the serum levels of 
catecholamines7, inflammatory cytokines8, and natriuretic peptides9. These promote lipolysis, proteolysis, and 
oxidative stress, the hallmarks of metabolic dysfunction in HF5,10 either directly or via the induction of insulin 
resistance, a principal metabolic feature of the HF pathophysiology11. Metabolic dysfunction and the catabolic 
dominance in HF are further intensified by a reduced appetite and an impaired intestinal nutrient absorption due 
to congestion and intestinal edema as well as the diminished biosynthetic capacity of the hypo-perfused and/or 
congested liver12–15.
The extent of the metabolic perturbation parallels the hemodynamic impairment, i.e. the severity of HF. 
Accordingly, it is conceivable that the metabolomic profile of the patients’ serum at admission may have a valua-
ble prognostic potential for 3-month mortality in AHF. Untargeted metabolic profiling using 1H nuclear magnetic 
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resonance (NMR) spectroscopy has been successfully established in the recent years for a wide range of metabo-
lites and biological matrices, including human biofluids16–20. The aim of the present study was therefore to employ 
NMR spectroscopy to identify serum metabolites that are prognostic for 3-month mortality in patients with AHF.
Results
Clinical characteristics, pre-admission medication and comorbidities. Out of 152 AHF patients 
recruited in the study21–24, serum samples of 130 patients were subjected to the metabolomic analyses. Of these, 32 
(24.6%) died within three months after onset of AHF. As presented in Table 1, body mass index (BMI) and weight 
were significantly lower and the liver enlargement and peripheral edema, were considerably more frequently 
observed in patients who did not survive compared to those who survived the first three months after onset of 
AHF. These groups were not significantly different regarding age, gender, smoking, New York Heart Association 
Functional Classification (NYHA), mean arterial pressure (MAP), heart rate, ejection fraction, or systolic pul-
monary artery pressure. The incidence of distended jugular veins and ascites as well as pre-admission medication 
were also similar in both groups (Table 1). Additionally, the groups did not differ with respect to the history of 
hyperlipidemia, hypercholesterolemia, hypertension, type 2 diabetes mellitus (T2DM), chronic obstructive pul-
monary disease, chronic kidney disease, cardiomyopathy, or acute coronary syndrome (Supplementary Table 1).
Laboratory parameters. While glomerular filtration rate (GFR) and total cholesterol were significantly 
lower, the serum levels of urea, creatinine, N-terminal pro brain natriuretic peptide (NT-proBNP), alanine ami-
notransferase (ALT), and aspartate aminotransferase (AST) were significantly higher in AHF patients who died 
within three months compared to those who survived three months after onset of AHF (Table 2). The two groups 
did not differ in the serum levels of proteins, albumin, interleukin-6 (IL-6), C-reactive protein (CRP), as well as 
low-density lipoprotein cholesterol (LDL cholesterol), high-density lipoprotein cholesterol (HDL-cholesterol), 
and triglycerides (Table 2).
Identification and prognostic value of metabolites differently abundant in patients who were 
alive and those who died within three months after onset of AHF. In order to assess metabolic 
differences between patients that did and did not die within three months after onset of AHF, nuclear magnetic 
resonance (NMR) metabolic profiling of 130 serum samples was performed. When comparing differences in 
metabolic fingerprints between patients who were alive and those who died within 3 months after onset of AHF, 
Orthogonal-Partial Least Squares - Discriminant Analysis (O-PLS-DA) revealed a slight clustering of patient 
samples with correlation coefficients R2 up to 0.18 and a Q2 of 0.104 (p < 0.01) (Fig. 1a). Reduced NMR spec-
tra revealed altered metabolites in normalized AHF serum samples (Fig. 1b) and indicated that the levels of 
All (N = 130) Alive (N = 98) Dead (N = 32) p-value
Age (years) 77.1 (45.5–96.7) 75.2 (45.5–93.0) 78.8 (50.9–96.7) 0.263
Female 67 (51.5%) 47 (48.0%) 20 (62.5%) 0.162
BMI (kg/m2) 28.4 (17.1–43.5) 29.0 (19.9–42.6) 25.4 (17.1–43.5) 0.017
Weight (kg) 80.0 (40.0–144.0) 84.5 (46.0–135.0) 72.5 (40.0–144.0) 0.001
Smoking 34 (26.2%) 28 (28.6%) 6 (18.8%) 0.356
NYHA class
2 11 (8.5%) 10 (10.2%) 1 (3.1%) 0.454
3 73 (56.2%) 55 (56.1%) 18 (56.2%)
4 46 (35.4%) 33 (33.7%) 13 (40.6%)
MAP (mmHg) 103.3 (65.0–160.0) 103.3 (65.0–160.0) 96.7 (70.0–150.0) 0.051
Heart rate (beats/min) 100.0 (36.0–160.0) 102.0 (36.0–160.0) 93.0 (60.0–140.0) 0.087
EF (%) 45.0 (20.0–70.0) 45.0 (20.0–70.0) 40.0 (20.0–70.0) 0.412
SPAP (mmHg) 45.0 (35.0–80.0) 45.0 (35.0–80.0) 50.0 (35.0–70.0) 0.144
JVD 46 (35.4%) 31 (31.6%) 15 (46.9%) 0.138
Enlarged liver 47 (36.2%) 30 (30.6%) 17 (53.1%) 0.033
Peripheral edema 89 (68.5%) 62 (63.3%) 27 (84.4%) 0.029
Ascites 20 (15.4%) 16 (16.3%) 4 (12.5%) 0.780
Statins 34 (26.2%) 24 (24.5%) 10 (31.2%) 0.490
ß-blockers 59 (46.5%) 41 (42.7%) 18 (58.1%) 0.152
ACEI 74 (56.9%) 56 (57.1%) 18 (56.2%) 1.000
Amplodipine 22 (17.1%) 19 (19.4%) 3 (9.7%) 0.279
Table 1. Baseline characteristics and pre-admission medication of AHF patients according to survival status 
after three months. Data are presented as n (%) or as median and range (minimum to maximum). Differences 
between the two groups were tested with Fisher’s exact test or the Mann-Whitney U test; significant differences 
are depicted in bold. AHF, acute heart failure; BMI, body mass index; EF, ejection fraction; JVD, jugular venous 
distension; MAP, mean arterial pressure; NYHA, New York Heart Association Functional Classification SPAP, 
systolic pulmonary artery pressure.
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2-hydroxybutyrate (2-HB), 3-hydroxybutyrate (3-HB), lactate, alanine, citrate, and tyrosine were higher, whereas 
valine and glucose were lower in patients who died within three months after onset of AHF.
In order to assess the prognostic value of these metabolites, the absolute concentrations were determined. As 
shown in Fig. 2 the levels of 2-HB, 3-HB, lactate, tyrosine, and citrate, but not of alanine, valine, and glucose, were 
significantly different (increased) in patients who died compared to those who survived the first three months 
after onset of AHF. Furthermore, sensitivity and specificity for each metabolite were assessed using Receiver 
Operating Characteristic (ROC) curves (Fig. 2). The highest values for the area under the curve (AUC), indicating 
highest predictivity, were obtained for tyrosine and citrate, followed by 3-HB, lactate, 2-HB, alanine, glucose, and 
valine (Fig. 2).
Correlation of 2-HB, 3-HB, lactate, citrate, and tyrosine concentrations with laboratory and 
clinical parameters. To examine the relationship between the identified metabolites, whose serum levels 
were significantly higher in patients who did not survive compared to those who survived the first three months 
after onset of AHF, and clinical and laboratory parameters, correlation analyses were performed. As shown in 
Table 3, the serum concentration of citrate, but not of any other metabolite, was significantly positively correlated 
with age, urea and creatinine as well as negatively correlated with fibrinogen, and HDL cholesterol. Both citrate 
and tyrosine were significantly negatively correlated with BMI, MAP, total cholesterol, LDL cholesterol, and tri-
glyceride levels. Citrate and 3-HB were negatively correlated with GFR but positively with urea. Additionally, 
2-HB, 3-HB, citrate, and tyrosine were significantly positively correlated with NT-proBNP. While only 2-HB 
and lactate were significantly positively correlated with ALT, all tested metabolites were significantly positively 
correlated with AST. Serum concentrations of 3-HB, citrate, and tyrosine, but not of 2-HB and lactate, were fur-
thermore significantly positively correlated with concentrations of IL-6.
Logistic regression analyses. To further examine the association of the metabolites with 3-month mortal-
ity, we performed logistic regression analyses (Table 4) for 2-HB, 3-HB, lactate, tyrosine, and citrate, the metab-
olites that were significantly higher (Fig. 2) in patients who did not survive three months after onset of AHF as 
compared to those that did. As shown in Table 4, the univariable analyses showed a significant positive associa-
tion of the serum levels of all tested metabolites with 3-month mortality. These associations remained significant 
for all tested metabolites except lactate, upon adjusting for the established prognostic parameters in HF, namely 
age, sex, BMI, T2DM, NT-proBNP, GFR, MAP, and LDL cholesterol.
Discussion
Despite established multivariable predictive models comprising patients’ characteristics, clinical signs and serum 
biomarkers, the estimation of risk in AHF is difficult, not accurate and poorly applicable in daily clinical prac-
tice25. Therefore, the identification of new biomarkers, which are related to the complex mechanisms of the AHF 
pathophysiology, may help in identifying high risk patients and initiating timely therapeutic interventions.
Considering a positive relationship between metabolic dysfunction, which is an established inherent feature of HF, 
and the extent of hemodynamic impairment, serum metabolites might be useful prognostic markers in AHF5,26,27.
In the present study, we show, that serum levels of 2-HB, 3-HB, citrate, and tyrosine are independently associ-
ated with 3-months mortality in AHF patients, even after adjusting for other well-known risk factors. Increased 
levels of these metabolites as well as lactate in AHF patients who did not survive the first three months after onset 
All (N = 130) Alive (N = 98) Dead (N = 32) p-value
GFR (ml/min/1.73 m2) 51.3 (15.0–105.7) 55.1 (16.0–105.7) 42.3 (15.0–77.0) 0.002
Urea (mmol/L) 8.0 (3.0–64.0) 8.0 (3.0–64.0) 14.0 (4.0–41.0) <0.001
Creatinine (µmol/L) 106.0 (53.0–273.0) 102.5 (53.0–255.0) 126.0 (66.0–273.0) 0.024
NT-proBNP (ng/mL) 8220.5 (171–70000) 6304 (171–70000) 15683.5 (3903–46054) <0.001
ALT (U/L) 23.0 (6.0–623.0) 20.0 (6.0–623.0) 25.0 (13.0–556.0) 0.008
AST (U/L) 27.0 (10.0–666.0) 25.0 (10.0–666.0) 36.5 (15.0–487.0) 0.001
Serum protein (g/L) 68.0 (31.0–87.0) 68.0 (31.0–87.0) 65.0 (53.0–79.0) 0.076
Albumin (g/L) 40.0 (22.0–62.0) 40.0 (22.0–62.0) 36.0 (24.0–62.0) 0.085
IL-6 (pg/mL) 18.9 (0.4–300.0) 18.4 (0.4–300.0) 24.4 (1.2–300.0) 0.283
CRP (µg/mL) 9.0 (0.2–247.4) 7.7 (0.2–247.4) 13.0 (1.1–169.0) 0.169
Total cholesterol (mmol/L) 3.8 (1.7–9.1) 4.2 (1.7–9.1) 3.6 (2.1–6.9) 0.018
LDL cholesterol (mmol/L) 2.3 (0.8–6.3) 2.4 (1.0–6.3) 2.0 (0.8–4.7) 0.067
HDL cholesterol (mmol/L) 1.0 (0.3–3.6) 1.0 (0.4–3.6) 0.8 (0.3–2.3) 0.053
Triglycerides
(mmol/L) 1.1 (0.6–4.3) 1.1 (0.6–4.3) 1.0 (0.6–3.0) 0.179
Table 2. Laboratory parameters of AHF patients according to survival status after three months. Data are 
presented as median and range (minimum to maximum). Differences between AHF patients who died and 
those who survived the first three months after onset of AHF were tested with the Mann-Whitney U test; 
significant differences are depicted in bold. ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
AHF, acute heart failure; CRP, C-reactive protein; GFR, glomerular filtration rate; IL-6, interleukin-6; LDL,  
low-density lipoprotein; HDL, high-density lipoprotein; NT-proBNP, N-terminal pro brain natriuretic peptide.
4Scientific RepoRts |          (2019) 9:6743  | https://doi.org/10.1038/s41598-019-42937-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
of AHF strongly indicate a more severe state of the disease and more severe systemic metabolic perturbations in 
this group of AHF patients, compared to AHF patients who survived 3 months after onset of AHF. Indeed, with 
the exception of lactate the levels of 2-HB, 3-HB, citrate, and tyrosine were significantly positively correlated with 
NT-proBNP, reflecting a positive relationship with the severity of HF28.
Figure 1. OPLS-DA plot of AHF serum samples. (a) Multivariate OPLS-DA plot of 3-month mortality.  
(b) Reduced NMR spectra reveal altered metabolites in normalized AHF serum samples. Positive covariance 
corresponds to metabolites present at increased concentrations, whereas negative covariance corresponds to 
decreased metabolite concentrations in patients that died within three months. Predictivity of the model is 
represented by R2. 1…2-hydroxybutyrate, 2…valine, 3…3-hydroxybutyrate, 4…lactate, 5…alanine, 6…citrate, 
7…glucose, 8…tyrosine.
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It is well established that a decreased cardiac output and a subsequent decreased tissue perfusion, a conse-
quence of left-sided HF, congestion, are accompanied by increased serum levels of catecholamines, natriuretic 
peptides and inflammatory cytokines. These, in turn trigger lipolysis, proteolysis, and oxidative stress, either 
directly or via the induction of insulin resistance7–11. Increased 2-HB levels have been shown to reflect insulin 
resistance and tricarboxylic acid (TCA) cycle overload29–31 as well as increased oxidative stress32,33. We observed 
increased serum levels of 2-HB in patients who died within three months after onset of AHF, which argues for the 
Figure 2. Serum levels and ROC analysis of altered metabolites. Differences between patients who were 
alive and those who died within three months after onset of AHF were tested with the Mann-Whitney U test. 
Absolute concentrations were used to calculate ROC curves for distinct metabolites and to assess the prognostic 
value of the distinct metabolites for 3-month mortality.
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role of insulin resistance and oxidative stress in metabolic perturbations and mortality in our AHF cohort. This 
is further substantiated by increased 3-HB levels in these patients, since its hepatic synthesis and serum levels are 
known to be augmented in states of insulin resistance and excess fatty acid supply31. Alternatively or additionally, 
Metabolites (µmol/L)
2-HB 3-HB Lactate Citrate Tyrosine n
Age (years)
r −0.04 0.07 −0.04 0.27 0.06 130
p 0.627 0.430 0.690 0.002 0.513
BMI (kg/m2)
r 0.00 −0.12 −0.12 −0.22 −0.23 130
p 0.989 0.185 0.162 0.012 0.009
MAP (mm Hg)
r −0.12 −0.07 −0.04 −0.27 −0.28 130
p 0.163 0.398 0.665 0.002 0.001
NT-proBNP (pg/mL)
r 0.18 0.25 0.13 0.43 0.28 124
p 0.043 0.004 0.141 <0.001 0.002
GFR (ml/min/1.73 m2)
r −0.10 −0.17 −0.15 −0.57 −0.12 129
p 0.243 0.049 0.085 <0.001 0.183
Urea (mmol/L)
r 0.14 0.22 −0.01 0.48 0.10 129
p 0.111 0.013 0.901 <0.001 0.274
Creatinine (mol/L)
r 0.13 0.17 0.13 0.51 0.09 129
p 0.139 0.050 0.147 <0.001 0.333
ALT (U/L)
r 0.19 0.16 0.19 0.03 0.16 128
p 0.034 0.064 0.032 0.746 0.080
AST (U/L)
r 0.21 0.27 0.29 0.20 0.32 129
p 0.019 0.002 0.001 0.025 <0.001
Fibrinogen (g/L)
r 0.13 −0.07 −0.09 −0.38 −0.13 126
p 0.149 0.447 0.311 <0.001 0.148
IL-6 (pg/mL)
r 0.09 0.18 0.12 0.22 0.22 130
p 0.285 0.045 0.188 0.010 0.013
Total cholesterol (mmol/L)
r −0.02 −0.17 0.03 −0.44 −0.21 130
p 0.802 0.054 0.726 <0.001 0.018
LDL-cholesterol (mmol/L)
r −0.01 −0.14 0.05 −0.35 −0.19 130
p 0.898 0.125 0.545 <0.001 0.030
HDL-cholesterol (mmol/L)
r −0.04 −0.03 0.10 −0.23 −0.06 130
p 0.686 0.745 0.274 0.009 0.470
Triglycerides (mmol/L)
r 0.02 −0.12 0.01 −0.23 −0.19 130
p 0.829 0.187 0.929 0.009 0.029
Table 3. Correlation analyses of 2-HB, 3-HB, lactate, citrate and tyrosine with clinical and laboratory 
parameters. Data are presented as Spearman correlation coefficient r, p-value, and number of available 
samples (n); significant correlations are depicted in bold. ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; BMI, body mass index; GFR, glomerular filtration rate; HDL, high-density lipoprotein; 2-HB, 
2-Hydroxybutyrate; 3-HB, 3-Hydroxybutyrate; IL-6, interleukin 6; LDL, low-density lipoprotein; MAP, mean 
arterial pressure; NT-proBNP, N-terminal pro brain natriuretic peptide.
Unadjusted Adjusteda
OR (95% CI) p-Value OR (95% CI) p-Value
2-HB (µmol/L) 7.14 (1.73–33.50) 0.009 10.29 (1.78–74.18) 0.013
3-HB (µmol/L) 2.42 (1.32–4.58) 0.005 2.15 (1.06–4.50) 0.034
Lactate (µmol/L) 4.36 (1.52–13.57) 0.008 3.64 (1.01–14.92) 0.057
Citrate (µmol/L) 26.24 (5.89–139.62) <0.001 11.74 (1.44–113.20) 0.026
Tyrosine (µmol/L) 24.48 (5.11–157.78) <0.001 34.70 (4.49–386.70) 0.002
Table 4. Logistic regression analyses of 3-month mortality for 2-HB, 3-HB, lactate, citrate, and tyrosine. aThe 
model was adjusted for age, sex, BMI, T2DM, NT-proBNP, GFR, MAP and LDL-cholesterol. Log-transformed 
values of the metabolite concentrations were used as covariates. The unadjusted analyses comprised data of 130 
patients (32 events) and the adjusted analyses data of 122 patients (29 events). Significant results are depicted 
in bold. BMI, body mass index; 2-HB, 2-Hydroxybutyrate; 3-HB, 3-Hydroxybutyrate; CI, confidence interval; 
LDL, low-density lipoprotein; MAP, mean arterial pressure; NT-proBNP, N-terminal pro brain natriuretic 
peptide; OR, odds ratio.
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increased 3-HB serum levels in this group of AHF patients may be a consequence of the decreased utilization of 
3-HB as an energy substrate in skeletal muscle. Previous studies have shown decreased 3-HB utilization in skeletal 
muscle of HF patients compared to healthy controls34.
Elevated serum 3-HB levels may result in an increased uptake and oxidation by the failing heart. This in turn 
may diminish the uptake and utilization of glucose35, whose energy producing efficiency outperforms that of 
3-HB36. Accordingly, by displacing glucose utilization, the elevated 3-HB might be detrimental when oxygen 
provision is limited due to decreased cardiac tissue perfusion and congestion, as is encountered in the failing 
heart. Furthermore, an increased intracellular pool of acetyl CoA, secondary to an increased 3-HB oxidation, may 
facilitate a hyperacetylated state in cardiac myocytes37. This in turn may lead to a posttranslational modification of 
enzymes involved in cellular energy metabolism, causing detrimental metabolic perturbations in the failing heart.
However, 3-HB has been shown to promote the myocardial blood flow in healthy humans35, and 3-HB is a 
natural inhibitor of class I histone deacetylases (HDAC)38. Since HDAC inhibitors can block cardiac fibrosis and 
thus improve diastolic function39,40, elevated 3-HB serum levels might be beneficial for the failing heart. Along 
these lines, it would be important to examine whether ketogenic diet-induced ketosis, reported to exert positive 
effects on cardiovascular risk in some but not all studies41, would be beneficial or detrimental in AHF.
Increased serum citrate levels in patients who died within three months after onset of AHF further substan-
tiate an increased supply of the liver and other tissues with fatty acids. Under this condition, an augmented fatty 
acid ß-oxidation gives rise to the increased levels of TCA cycle intermediates, including citrate. Citrate is a known 
potent allosteric inhibitor of pyruvate dehydrogenase which is why increased intracellular citrate levels redirect 
the conversion of pyruvate from acetyl coenzyme A to lactate, consequently leading to increased lactate plasma 
levels42,43. Indeed, the lactate serum levels were higher in AHF patients who died within three months after onset 
of AHF compared to those who survived and were significantly positively correlated with citrate serum levels 
(r = 0.37, p < 0.001). Besides high intracellular citrate levels, diminished oxygen supply to the tissue due to a 
decreased tissue perfusion and congestion, which are both hemodynamic hallmarks of HF, augments anaerobic 
glycolysis and lactate production44. In the present study, the association of lactate serum levels with 3-month mor-
tality did not remain significant (p = 0.061) after adjusting for parameters which are associated with mortality in 
HF patients. This is in contrast with findings of a recent study that showed a significant association of lactate with 
1-year mortality in AHF patients45. A possible explanation for this discrepancy is that lactate may have more of a 
long-term rather than a short-term prognostic capacity for mortality in AHF.
The serum levels of tyrosine at admission were also higher in patients who died within three months com-
pared to those who were alive three months after onset of AHF. In the present study, tyrosine serum levels were 
significantly positively correlated with the serum levels of NT-proBNP, IL-6, and 2-HB (r = 0.24, P = 0.007), the 
markers of HF severity, inflammation, and oxidative stress, respectively, which are known to be associated with 
increased muscle proteolysis and protein turnover46,47. However, the fact that the serum levels of other amino 
acids were similar in the two patient groups presents an argument against the breakdown of proteins in the 
skeletal muscle being responsible for increased tyrosine serum levels in AHF patients that did not survive for 
three months. Therefore, the decreased uptake and use of tyrosine as a substrate for the biosynthesis of various 
biological molecules, including thyroid hormones, catecholamines, neurotransmitters, or serum proteins48, may 
better explain higher tyrosine serum levels in the group of patients who died within three months after onset 
of AHF. We observed a significant positive correlation of the tyrosine serum levels with AST and a significant 
negative correlation with serum fibrinogen levels in the present study. These strongly argue for a contribution 
of an impaired liver function and hepatocyte damage, possibly due to hypoperfusion and/or congestion, to the 
increased tyrosine serum levels. This is in line with results of previous studies showing that a decreased liver 
function and/or damage to the liver result in increased serum levels of tyrosine and other aromatic amino acids49.
Besides tyrosine, we observed positive correlations of 3-HB, 2-HB, lactate, and citrate with serum levels of 
liver transaminases, which are known to be increased as a consequence of hepatocyte damage due to reduced per-
fusion14. This suggests that not only the increased production but also a lower uptake by the liver as well as an aug-
mented release from damaged hepatocytes likely contribute to the increased serum levels of those metabolites44.
The serum levels of citrate and 3-HB were negatively correlated with GFR, suggesting that the renal excretion 
might be factor in the regulation of the serum levels of these metabolites in AHF. Alternatively, the negative 
relationship between the levels of these metabolites and GFR may conceivably be a consequence of their opposite 
regulation by the HF pathophysiology, which most likely also explains the negative correlations of both citrate 
and tyrosine with various serum lipids, BMI, and MAP, which are frequently decreased in HF50.
This study is not free of limitations: Due to the study design we could not examine the mechanistic relation-
ship between the underlying pathophysiological processes and the serum levels of the identified metabolites. In 
addition, our metabolic profiles are just a snap shot of the patients’ metabolic state at hospital admission without 
capturing dynamic changes in the levels of the metabolites during hospitalization. Thus we are unable to assess 
any temporal development or the impact of therapeutic interventions. Furthermore, we have no data on the 
patients’ nutritional state, i.e. whether and how long they were fasting before blood collection. Moreover, we pro-
filed only water-soluble metabolites without addressing lipid metabolites. Finally, because the statistical power 
of our analyses is affected by the moderate number of available serum samples (n = 130), our results need to be 
confirmed in further and larger studies.
We conclude that serum levels of 2-HB, 3-HB, tyrosine, and citrate are associated with increased 3-month 
mortality in AHF patients and might thus be of prognostic value in AHF.
Methods
Study design and patients. Details of the study and its patient cohort have already been described in 
depth21–24. We conducted a prospective observational single-center study including consecutive hospitalized AHF 
patients. Written informed consent was obtained from all patients. The study was conducted in adherence to the 
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ethical guidelines of the Declaration of Helsinki51, and was approved by the Ethics Committees of the University 
Hospital Centre Sisters of Charity, Zagreb, Croatia and the Medical University of Graz, Austria. The patients were 
treated by local standard operating procedures outlined by the ESC Guidelines for AHF3,52.
Laboratory procedures. The blood sampling and laboratory methods have already been described in pre-
vious reports on our AHF cohort21–24.
NMR metabolic profiling. To remove serum proteins and to quench enzymatic reactions in the sam-
ples 200 µL serum were mixed with 400 µL methanol and stored at −20 °C for 7 days until further processing. 
Afterwards the samples were spun at 17949 rcf at 4 °C for 30 minutes. Supernatants were lyophilized and mixed 
with 500 μL of NMR buffer in D2O and transferred to 5 mm NMR tubes. Metabolites were measured as described 
previously53.
Spectral acquisition was performed on a 600 MHz Bruker Avance Neo NMR spectrometer equipped with 
a TXI 600S3 probehead and processing was performed as previously described53. Spectra pre-processing and 
data analysis have been carried out as previously described54 using Principle Component Analysis (PCA), 
O-PLS-DA55, and all associated data consistency checks as well as 7-fold cross-validation. In order to validate the 
statistical significance of the determined differences between patients that did and did not survive three months, 
the quality assessment statistic Q2 is reported. This measure provides information about cross-validation and 
is a qualitative measure of consistency between the predicted and original data, with a maximum value of 1. 
Processed spectra were imported into MestreNova 12.0.2 in order to quantify metabolites of interest. Glucose 
quantification was performed using Chenomx Professional 8.0 with the existing Chenomx library.
Statistical analyses. Patients’ baseline characteristics, laboratory parameters, and metabolite serum levels 
were descriptively analyzed using absolute and relative frequencies or median and range. Differences between 
patients who did and did not survived the first three months after onset of AHF were assessed either by Fisher’s 
exact or the Mann-Whitney U test. Correlations between the metabolites and various clinical and laboratory 
parameters were determined by the Spearman correlation coefficient. Metabolite concentrations were used to 
perform an ROC curves analysis in MetaboAnalyst 4.056. Additionally, the impact of the metabolites on 3-month 
mortality was examined using univariable as well as multivariable logistic regression analyses. The latter was 
adjusted for age, sex, BMI, T2DM, NT-proBNP, GFR, MAP as well as LDL cholesterol. Odds ratios (OR) along 
with the respective 95% confidence intervals (CI) are presented. In order for the resulting ORs to be on an inter-
pretable scale, all metabolites were log-transformed for the regression analyses. The variance inflation factor was 
used to assess the degree of multi-collinearity in the models. R version 3.4.4 was used for the statistical analyses.
All methods were carried out in accordance with the relevant guidelines and regulations.
Data Availability
All data generated or analysed during this study are included in this manuscript.
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